Clinical trial Recruiting at 1 site Interventional

Long-read genome sequencing to help diagnose dystonia

Official title: Evaluation of the Value of Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia: a Prospective Multicenter Study

Run by University Hospital, Strasbourg, France · NCT06999096 · Data updated 2026-11-12

Researchers test long-read genome sequencing to see if it can provide a genetic diagnosis for people with dystonia and related movement disorders when standard tests have not.

Quick facts

Study typeInterventional
SexAll
Enrollment150 (estimated)
SponsorUniversity Hospital, Strasbourg, France
Academic / other
Locations4 sites (Montpellier and 3 other locations)
StatusRecruiting
StartedApril 22, 2026
Main results expectedAugust 2030
Study endsAugust 2030
Registry record updatedMay 20, 2026
Trial IDNCT06999096 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals with familial or early-onset dystonia who have already undergone short-read genome sequencing without a molecular diagnosis, and who have available blood samples from the index case and at least two relatives.

Probably not a fit

Patients without a detectable genetic cause or those unable to provide required family samples may not receive a diagnostic benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses long-read whole-genome sequencing to detect genetic causes of dystonia in patients and their families who previously had inconclusive results with short-read sequencing. It targets individuals with familial dystonia or early-onset forms, requiring at least two relatives' participation and prior negative short-read testing. The goal is to improve diagnostic yield, inform genetic counseling, and guide prognosis and potential targeted therapies. The study is conducted across multiple French centers with a lead sponsor at University Hospital, Strasbourg, and collaborators at Montpellier, Nancy, and Paris sites.

Why it matters

Potential benefit: If successful, participants may receive a definitive genetic diagnosis that can inform prognosis, family planning, and potential targeted treatment options.

How similar studies have gone: Prior studies suggest that long-read sequencing can uncover variants missed by short-read methods, though the approach is still being evaluated in dystonia.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria - Index case:

* Index case affected by familial dystonia (≥1 first-degree relative affected) and/or sporadic early-onset dystonia (symptom onset before age 50), meeting the criteria of the PFMG-2025 program.
* Index case who has undergone short-read genome sequencing, which did not lead to a molecular diagnosis.
* Ability to understand and sign informed consent by the index case and/or their parents or legal guardians for patients under 18 years of age.
* Availability of a blood sample from the index case and at least two relatives, either affected or unaffected.

Inclusion criteria - Relatives:

* Symptomatic or asymptomatic relative of an index case, who has also undergone short-read genome sequencing without a conclusive molecular diagnosis.
* Ability to understand and sign informed consent.

Exclusion criteria:

* Index case or relatives who are not affiliated with or not beneficiaries of a social security scheme.
* Index case and their parents presenting with a condition that, in the opinion of the investigator, would contraindicate participation in the study.
* Suspected non-genetic etiology (e.g., perinatal hypoxic-ischemic injury, kernicterus, history of severe head trauma or central nervous system infection).

Where it's running

  • CHRU Nancy
    Nancy, France
    Recruiting
  • CHU de Montpellier - Hôpital Gui de Chauliac
    Montpellier, France
    Not yet recruiting
  • Hôpital Pitié Salpêtrière- APHP
    Paris, France
    Not yet recruiting
  • Hôpitaux Universitaires de Strasbourg
    Strasbourg, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.